North American Palladium Ltd. (PAL) -0.07

Trade PAL
NOW!
Last Trade:4.18Short Ratio:0.30
Last Trade Time:4:00pmDay Range:4.10 - 4.24
Ask:Year Range:1.03 - 4.78
Bid:One Year Target:5.50
Open:4.18Exchange:AMEX
Volume:1342934EBITDA:-26.7M
Prev. Close:4.25Market Cap:528.7M
50 Day Moving:4.00Div Yield:
200 day moving:3.2962PE:

Related RealMoney articles from TheStreet.com

Spot Gold Prices Gain Traction
Palladium Rides High on Auto Recovery
Spot Metals Extend Gains

Diamyd Medical: Diamyd US Phase III Study Well under Way

Posted on 03/10/10 at 2:39am
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News:
Click here to read the rest of the article

Diamyd Medical: Diamyd Terminates Liquidity Provider Agreement

Posted on 03/04/10 at 2:36am
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Diamyd Medical (STO:DIAMB)(Pink Sheets:DMYDY):
Click here to read the rest of the article

Jim Cramer Comments On PMCS, CSCO, VRTX, GILD, PAL

Posted on 03/03/10 at 7:32pm
CNBC Mad Money's Jim Cramer said in the segment of his show called Lightning Round OT that he believes PMC-Sierra, Inc. (NASDAQ: PMCS) is making a comeback. He added that products that PMCS makes are used by Cisco Systems, Inc. (NASDAQ: CSCO), and investors should buy CSCO too. Cisco Systems, Inc.
Click here to read the rest of the article
Posted in

PicksThatMove.com Announces Investment Opinion on Breakwater Resources Ltd., First Gold Exploration Inc., North American Palladium Ltd. and Conolog Corporation

Posted on 02/03/10 at 6:44am
CALGARY, Alberta--(BUSINESS WIRE)-- The investment opinions offered below and in this press release are provided by Nick Hunter, RIA, of Picksthatmove.com.
Click here to read the rest of the article

Diamyd Medical: Diamyd Informs in Quarterly Report of the Objective to File for Market Approval for the Diamyd® Diabetes Vaccine in 2011

Posted on 01/29/10 at 3:18am
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical (STO:DIAMB), says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.
Click here to read the rest of the article